Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, and glucagon) still in phase 3 trials, whilst tesamorelin is a synthetic GHRH analogue licensed only for HIV-associated lipodystrophy in the US
But do these all-natural alternatives really yield benefits similar to those of their pharmaceutical counterparts
GLP-1 patches are often promoted and marketed by social media influencers as cheaper versions of weight loss injections, but they do not contain any GLP-1 mimicking ingredients, and there is little scientific evidence to prove they really work
Side effect profiles between Semaglutide and Retatrutide show similar gastrointestinal patterns, though Semaglutide demonstrates slightly higher nausea rates (44% versus 28%) at comparable efficacy doses
Current Candidates for Tirzepatide Because tirzepatide is accessible right now, it is the primary consideration for: Individuals requiring immediate intervention for class II or class III obesity
Providers adjust plans over time based on ongoing progress
